Myriad Pushing Ahead With Payors on GeneSight as Data From Large Randomized Study is Published

Jan 07, 2019

|

NEW YORK (GenomeWeb) – Myriad Genetics is hoping that data from a large randomized controlled study published last week on GeneSight will change the reimbursement prospects for the pharmacogenetic test, as well as shift the standard of care for treating depression.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Some More Than Others

A new analysis finds some cancers receive more nonprofit dollars than others.

Another Look

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

Gene Variant's Possible Role

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

Science Finds Sex-Biased Gene Expression in Mammals, More

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.

Menu